Home/Pipeline/mRNA Therapeutics Platform Application

mRNA Therapeutics Platform Application

Not Specified

ResearchActive

Key Facts

Indication
Not Specified
Phase
Research
Status
Active
Company

About Lupagen

Lupagen is pioneering an extracorporeal bedside delivery platform aimed at transforming the administration of cell and gene therapies. Its Xynvivo™ System enables a simplified, potentially lower-cost process that can be applied to both ex vivo cell therapy and in vivo gene therapy programs, addressing critical industry pain points like high manufacturing costs, complex logistics, and safety concerns related to systemic vector administration. By offering a combination of proprietary technology and collaborative services from preclinical through commercial stages, Lupagen seeks to expand patient access and provide biopharma partners with a differentiated and accelerated path to market.

View full company profile

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved